fda warning compounding semaglutide september 2025 Diabetes advocacy group discourages use of compounded GLP-1 drugs FDA warns against compounded GLP-1

In a letter (PDF) to shareholders, executives said the company has a legal pathway to sell "personalized titration schedules and dosage levels that are not essentially copies of commercially available medications" that allow providers to "meet the needs of individual patients regardless of shortage dynamics." Hims & Hers said revenue from its non-GLP-1 offerings totaled $1.2 billion of the $1.48 billion that it brought in last year, suggesting the company sold roughly $200 million in compounded GLP-1 drugs last year

The stock is a no-brainer buy

PMID: 39275170

248 : 69666972 Colucci WJ, Gandour RD

Check with your prescription drug plan about out-of-pocket costs like deductibles, copays, or coinsurance costs

Risk tolerance is a key factor in determining your asset allocation